Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:ATRA NASDAQ:CLLS NASDAQ:INBX NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.73+7.5%$2.46$1.78▼$10.14$57.03M0.7274,706 shs107,528 shsATRAAtara Biotherapeutics$9.30+0.8%$7.94$5.01▼$18.70$55.44M0.18121,702 shs30,021 shsCLLSCellectis$2.15+35.2%$1.49$1.10▼$2.43$119.50M2.91224,830 shs1.27 million shsINBXInhibrx Biosciences$22.96+5.5%$14.27$10.80▼$23.18$332.46M-0.04105,425 shs162,890 shsKRYSKrystal Biotech$150.41+1.5%$135.82$122.80▼$219.34$4.35B0.67320,772 shs265,292 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%+6.50%+3.25%-25.95%-67.89%ATRAAtara Biotherapeutics0.00%+15.23%+4.65%+57.78%-11.84%CLLSCellectis0.00%+0.32%+19.55%+6.00%-23.92%INBXInhibrx Biosciences0.00%+33.68%+49.42%+83.25%+63.81%KRYSKrystal Biotech0.00%+3.61%+8.10%-12.28%-27.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.5706 of 5 stars3.44.00.04.82.72.50.6ATRAAtara Biotherapeutics4.5971 of 5 stars3.33.00.04.74.42.50.6CLLSCellectis3.4421 of 5 stars3.54.00.00.03.32.50.6INBXInhibrx Biosciences2.2504 of 5 stars0.03.00.04.62.21.71.3KRYSKrystal Biotech4.6549 of 5 stars3.51.00.04.72.93.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$23.80771.79% UpsideATRAAtara Biotherapeutics 2.57Moderate Buy$17.7590.86% UpsideCLLSCellectis 3.00Buy$4.0086.05% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AKRYSKrystal Biotech 3.00Buy$213.7542.11% UpsideCurrent Analyst Ratings BreakdownLatest KRYS, CLLS, INBX, ATRA, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.006/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M57.03N/AN/A$3.40 per share0.80ATRAAtara Biotherapeutics$199.73M0.28N/AN/A($16.89) per share-0.55CLLSCellectis$49.22M2.43N/AN/A$2.36 per share0.91INBXInhibrx Biosciences$200K1,662.30$120.84 per share0.19$9.23 per share2.49KRYSKrystal Biotech$290.52M14.96$4.71 per share31.95$32.90 per share4.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)ATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)CLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1636.1614.92N/A37.17%14.64%13.28%8/4/2025 (Estimated)Latest KRYS, CLLS, INBX, ATRA, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ADVMAdverum Biotechnologies-$2.24N/AN/AN/AN/AN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32N/AN/AN/A$4.23 millionN/A8/5/2025N/ACLLSCellectis-$0.15N/AN/AN/A$10.07 millionN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A3.573.57ATRAAtara BiotherapeuticsN/A0.570.57CLLSCellectis0.441.671.67INBXInhibrx Biosciences1.045.125.12KRYSKrystal BiotechN/A9.659.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%INBXInhibrx Biosciences82.46%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%ATRAAtara Biotherapeutics4.00%CLLSCellectis16.41%INBXInhibrx BiosciencesN/AKRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.64 millionOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableKRYS, CLLS, INBX, ATRA, and ADVM HeadlinesRecent News About These CompaniesKrystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitisJuly 14 at 11:49 AM | ophthalmologytimes.comOKrystal Biotech, Inc. (NASDAQ:KRYS) Holdings Cut by TimesSquare Capital Management LLCJuly 14 at 8:54 AM | marketbeat.comWilliam Blair Forecasts Lower Earnings for Krystal BiotechJuly 14 at 2:39 AM | marketbeat.comWilliam Blair Reduces Earnings Estimates for Krystal BiotechJuly 13 at 2:17 AM | americanbankingnews.comSuma Krishnan Sells 200 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockJuly 12 at 6:25 AM | insidertrades.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 200 Shares of StockJuly 11 at 7:52 PM | marketbeat.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 6,927 Shares of StockJuly 11 at 7:52 PM | marketbeat.comCiti raises Krystal Biotech stock price target to $176 on KB801 trial ...July 11 at 6:11 AM | investing.comQ2 EPS Estimates for Krystal Biotech Decreased by AnalystJuly 11 at 5:48 AM | marketbeat.comKRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock UpJuly 10, 2025 | zacks.comPrincipal Financial Group Inc. Has $22.78 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)July 10, 2025 | marketbeat.comPittsburgh tech's future isn't guaranteed, CEO warnsJuly 9, 2025 | msn.comKrystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic KeratitisJuly 9, 2025 | globenewswire.comAllspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)July 9, 2025 | marketbeat.comHigh Insider Ownership In 3 Promising Growth CompaniesJuly 8, 2025 | finance.yahoo.comAnalysts Offer Predictions for Krystal Biotech Q2 EarningsJuly 4, 2025 | americanbankingnews.comKrystal Biotech Inc. Research & Ratings | KRYS - Barron'sJuly 3, 2025 | barrons.comKrystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?July 3, 2025 | finance.yahoo.comClear Street Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationJuly 3, 2025 | msn.comPeering Into Krystal Biotech's Recent Short InterestJuly 3, 2025 | benzinga.comKrystal Biotech Q2 EPS Estimate Lowered by HC WainwrightJuly 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS, CLLS, INBX, ATRA, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.73 +0.19 (+7.48%) Closing price 04:00 PM EasternExtended Trading$2.71 -0.02 (-0.59%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara Biotherapeutics NASDAQ:ATRA$9.30 +0.07 (+0.76%) Closing price 04:00 PM EasternExtended Trading$9.41 +0.11 (+1.24%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Cellectis NASDAQ:CLLS$2.15 +0.56 (+35.22%) Closing price 04:00 PM EasternExtended Trading$2.08 -0.07 (-3.44%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Inhibrx Biosciences NASDAQ:INBX$22.96 +1.19 (+5.47%) Closing price 04:00 PM EasternExtended Trading$23.46 +0.50 (+2.17%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$150.41 +2.24 (+1.51%) Closing price 04:00 PM EasternExtended Trading$150.99 +0.58 (+0.39%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.